Bradmer Announces Third Quarter Operational and Financial Results
(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 10/29/12 -- Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") (TSX VENTURE: BMR.H) today announced its third quarter 2012 operational and financial results.
Operational Highlights
On December 21, 2011, Bradmer announced that it had entered into a letter of intent dated December 20, 2011 to complete a business combination with Epic Production Technologies International Inc. On June 12, 2012 the Company announced that Epic and Bradmer had agreed to terminate the letter of intent between the parties.
The directors and officers of Bradmer continue to seek out new opportunities in the ongoing process of identifying and completing an appropriate business transaction with a view to creating value for Bradmer and its shareholders.
Financial Results
Amounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").
For the three months ended September 30, 2012, we recorded a net loss of $77,000 or $0.004 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to a net loss of $102,000 or $0.005 per common share for the quarter ended September 30, 2011 based on the weighted average outstanding shares of 19,659,726.
Research and development expenses totaled $NIL in the three months ended September 30, 2012, compared to $2,000 in the third quarter of 2011 consisting of patent and consulting fees of $2,000. These costs were incurred in connection with the termination of the Duke License Agreement.
General and administrative expenses were $62,000 in the three months ended September 30, 2012 compared to $135,000 in the same quarter of the prior year. Major expenses in 2012 consisted of consulting fees of $18,000, directors' and officers' liability insurance premiums of $15,000, legal fees of $9,000 and audit fees of $6,000. In 2011, consulting fees were $41,000, legal fees amounted to $24,000, primarily related to the annual and special meeting of shareholders, and insurance premiums were $32,000. Stock-based compensation for the award of stock options in the quarter was $22,000.
The $15,000 foreign exchange loss in 2012 contrasted with the $35,000 foreign exchange gain in 2011.
For the nine months ended September 30, 2012, we recorded a net loss of $186,000 or $0.009 per common share based on the weighted average outstanding shares of 19,659,726 during the nine month period, compared to a net loss of $257,000 or $0.013 per common share for the nine months ended September 30, 2011 based on the same weighted average outstanding shares. The reduced loss in 2012 is attributable to the $85,000 reduction in general and administrative expenses.
Research and development expenses totaled $NIL in the nine months ended September 30, 2012, compared to $28,000 in the same period of 2011. Consulting fees were $12,000 and patent fees were $15,000. These costs were incurred in connection with the termination of the Duke License Agreement.
General and administrative expenses were $172,000 in the nine months ended September 30, 2012 compared to $257,000 in the same period of the prior year. Major expenses in 2012 consisted of consulting fees of $55,000, insurance premiums of $44,000, legal fees of $30,000, audit fees of $20,000 and transfer agent and stock exchange listing fees of $18,000. In 2011, legal fees amounted to $208,000, of which $157,000 was incurred in connection with the P1 Energy transaction, consulting fees were $72,000 and insurance premiums were $68,000. The recovery of P1 Energy transaction costs partially offset these expenses. Stock-based compensation was $22,000 and stock exchange listing fees were $12,000.
The $15,000 foreign exchange loss in 2012 contrasted with the $28,000 foreign exchange gain in 2011.
Our operational activities for the quarter ended September 30, 2012 were financed by cash on hand. We had available cash of $1,030,000 at September 30, 2012, compared to cash of $1,192,000 at December 31, 2011. The decrease was due to the $172,000 operating loss incurred in the period.
As at October 29, 2012, we have 19,659,726 common shares and options to purchase 1,955,000 common shares outstanding.
Additional information about Bradmer, including the MD&A and financial results may be found on SEDAR at .
Bradmer's common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.
Except for historical information, this news release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Contacts:
Bradmer Pharmaceuticals Inc.
Paul Van Damme
Chief Financial Officer
1.647.629.0136
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2012 - 15:01 Uhr
Sprache: Deutsch
News-ID 1164944
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 101 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bradmer Announces Third Quarter Operational and Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Bradmer Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
